BioCentury | Feb 24, 2021
Product Development

Insilico’s IPF candidate links, and tests, AI-led target and compound discovery

...big data with computer-generated chemical designs will increase the chances of success in the clinic.On Wednesday, Insilico Medicine Inc....
...and chemistry at Shanghai Medicilon Inc. (Shanghai:688202) and head of chemistry at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Karen Tkach Tuzman Insilico Medicine Inc. Pulmonary Pulmonary...
BioCentury | Feb 23, 2021
Management Tracks

Kite’s Takeshita to head R&D for Daiichi Sankyo; plus TScan adds CFO Silver, Hahn joins Blackfynn’s board and moves at Intercept, Kira, Insilico, BioXcel and Re-Vana

...of hematology and Zhang was general manager of Greater China. Hong Kong-based AI drug discovery company, Insilico Medicine Inc....
BioCentury | Jan 9, 2021
Tools & Techniques

What DeepMind’s leap means for structure-based drug developers

...Nimbus In contrast, AI plays Atomwise Inc. and Insilico Medicine Inc....
...boost ligand discovery will also vary by platform.Insilico Medicine Inc....
...Inc. Relay Therapeutics Inc. Neoleukin Therapeutics Inc. University of Washington Atomwise Inc. Insilico Medicine Inc. Nimbus...
BioCentury | Dec 23, 2020
Deals

Insilico caps year of deals by opening its computational platforms to pharmas’ in-house teams

...partners’ behalf, Insilico Medicine has launched versions of its platforms that pharmas can use themselves.This year, Insilico Medicine Inc....
...to incorporate the latter’s multi-omics dataset for cardiometabolic diseases into its target discovery platform. Karen Tkach Tuzman Insilico Medicine Inc. Johnson...
BioCentury | Nov 13, 2020
Deals

Nov. 12 Quick Takes: MorphoSys, UCB bring in new tech via deals; plus Cevec-Roche, Bridge-BI, Affimed-Roivant, Insilico-J&J, TCR2-ElevateBio

...be eligible for $2 billion in milestones, plus tiered royalties.Insilico in AI discovery deal with J&J Insilico Medicine Inc....
...2019 with plans to speed up innovation in cell and gene therapy.TargetsENPP2 (ATX) - autotaxin BC Staff BBT-877 Affimed Roivant Sciences Insilico Medicine Inc. Johnson...
BioCentury | Oct 13, 2020
Product Development

Data Bytes: coronavirus-targeted small molecules

...five other companies have SARS-CoV-2 3CLpro inhibitors in preclinical development: Anivive Lifesciences Inc., Cocrystal Pharma Inc. (NASDAQ:COCP), Insilico Medicine Inc....
BioCentury | Sep 3, 2020
Finance

Sept. 2 Quick Takes: Taysha files for IPO; plus DCVC’s Barclay joins Cohen’s Point72, Erasca, Deep Longevity and more

...than two months after its launch for HK$29.6 million ($3.8 million). Deep Longevity emerged from Insilico Medicine Inc....
BioCentury | Jul 22, 2020
Emerging Company Profile

Deep Longevity: Insilico spinout clocks biological age

...provide much insight into health status and are not very responsive to intervention. Parent company Insilico Medicine Inc....
...Therapeutics: an AI-based Platform to Reverse Cellular Aging” ). Danielle Golovin, Staff Writer University of California Los Angeles Insilico Medicine Inc. Human...
BioCentury | Jul 16, 2020
Emerging Company Profile

Fountain Therapeutics: an AI-based platform to reverse cellular aging

...CDKN2A (see “Slaying Senescent Cells” ). Deep Longevity Inc., a new subsidiary spinning out of Insilico Medicine Inc....
BioCentury | Apr 29, 2020
Product Development

April 28 Quick Takes: Syndax gains on leukemia data; plus Supernus, Neurocrine, Avadel, Insilico-Astellas, Innovent-Lilly, Chimerix

...clinical daytime sleepiness scores and decreased mean weekly cataplexy attacks. Insilico, Astellas in AI deal Insilico Medicine Inc....
Items per page:
1 - 10 of 38
BioCentury | Feb 24, 2021
Product Development

Insilico’s IPF candidate links, and tests, AI-led target and compound discovery

...big data with computer-generated chemical designs will increase the chances of success in the clinic.On Wednesday, Insilico Medicine Inc....
...and chemistry at Shanghai Medicilon Inc. (Shanghai:688202) and head of chemistry at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Karen Tkach Tuzman Insilico Medicine Inc. Pulmonary Pulmonary...
BioCentury | Feb 23, 2021
Management Tracks

Kite’s Takeshita to head R&D for Daiichi Sankyo; plus TScan adds CFO Silver, Hahn joins Blackfynn’s board and moves at Intercept, Kira, Insilico, BioXcel and Re-Vana

...of hematology and Zhang was general manager of Greater China. Hong Kong-based AI drug discovery company, Insilico Medicine Inc....
BioCentury | Jan 9, 2021
Tools & Techniques

What DeepMind’s leap means for structure-based drug developers

...Nimbus In contrast, AI plays Atomwise Inc. and Insilico Medicine Inc....
...boost ligand discovery will also vary by platform.Insilico Medicine Inc....
...Inc. Relay Therapeutics Inc. Neoleukin Therapeutics Inc. University of Washington Atomwise Inc. Insilico Medicine Inc. Nimbus...
BioCentury | Dec 23, 2020
Deals

Insilico caps year of deals by opening its computational platforms to pharmas’ in-house teams

...partners’ behalf, Insilico Medicine has launched versions of its platforms that pharmas can use themselves.This year, Insilico Medicine Inc....
...to incorporate the latter’s multi-omics dataset for cardiometabolic diseases into its target discovery platform. Karen Tkach Tuzman Insilico Medicine Inc. Johnson...
BioCentury | Nov 13, 2020
Deals

Nov. 12 Quick Takes: MorphoSys, UCB bring in new tech via deals; plus Cevec-Roche, Bridge-BI, Affimed-Roivant, Insilico-J&J, TCR2-ElevateBio

...be eligible for $2 billion in milestones, plus tiered royalties.Insilico in AI discovery deal with J&J Insilico Medicine Inc....
...2019 with plans to speed up innovation in cell and gene therapy.TargetsENPP2 (ATX) - autotaxin BC Staff BBT-877 Affimed Roivant Sciences Insilico Medicine Inc. Johnson...
BioCentury | Oct 13, 2020
Product Development

Data Bytes: coronavirus-targeted small molecules

...five other companies have SARS-CoV-2 3CLpro inhibitors in preclinical development: Anivive Lifesciences Inc., Cocrystal Pharma Inc. (NASDAQ:COCP), Insilico Medicine Inc....
BioCentury | Sep 3, 2020
Finance

Sept. 2 Quick Takes: Taysha files for IPO; plus DCVC’s Barclay joins Cohen’s Point72, Erasca, Deep Longevity and more

...than two months after its launch for HK$29.6 million ($3.8 million). Deep Longevity emerged from Insilico Medicine Inc....
BioCentury | Jul 22, 2020
Emerging Company Profile

Deep Longevity: Insilico spinout clocks biological age

...provide much insight into health status and are not very responsive to intervention. Parent company Insilico Medicine Inc....
...Therapeutics: an AI-based Platform to Reverse Cellular Aging” ). Danielle Golovin, Staff Writer University of California Los Angeles Insilico Medicine Inc. Human...
BioCentury | Jul 16, 2020
Emerging Company Profile

Fountain Therapeutics: an AI-based platform to reverse cellular aging

...CDKN2A (see “Slaying Senescent Cells” ). Deep Longevity Inc., a new subsidiary spinning out of Insilico Medicine Inc....
BioCentury | Apr 29, 2020
Product Development

April 28 Quick Takes: Syndax gains on leukemia data; plus Supernus, Neurocrine, Avadel, Insilico-Astellas, Innovent-Lilly, Chimerix

...clinical daytime sleepiness scores and decreased mean weekly cataplexy attacks. Insilico, Astellas in AI deal Insilico Medicine Inc....
Items per page:
1 - 10 of 38